PharmAust: Completes investigations on COVID-19 infection agent
- PharmAust (PAA) has investigated the effects of monepantel (MPL) and monepantel sulfone (MPLS) on SARS-CoV2 infection, the causal agent of COVID-19
- The three labs investigated SARS-CoV2-induced cell death, SARS-CoV2 RNA release from the cell and SARS-CoV2 RNA infection of neighbouring cells
- All three investigations demonstrated both monepantel (MPL) and monepantel sulfone (MPLS) protect against cell death in vitro, following infection with SARS-CoV2
- Two laboratories also investigated the effects of MPL and MPLS on early stages of the lifecycle by examining RNA release into the culture media
- The company was up 8.25 per cent, trading at 10.5 cents per share at 2:30 pm AEST
